Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441208 | 0.96 | DGAT1 (0.54) | DGAT1NPSR1 | |
| SCHEMBL441298 | 0.92 | DGAT1 (0.50) | DGAT1NPSR1 | |
| SCHEMBL4918435 | 0.90 | DGAT1 (0.56) | DGAT1KMT2AMEN1 | |
| SCHEMBL441132 | 0.89 | DGAT1 (0.59) | DGAT1KMT2AMEN1 | |
| SCHEMBL437636 | 0.89 | DGAT1 (0.49) | DGAT1EPHX2 | |
| SCHEMBL440825 | 0.87 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL442538 | 0.86 | DGAT1 (0.59) | DGAT1KMT2AMEN1DRD2 | |
| SCHEMBL441480 | 0.86 | DGAT1 (0.55) | DGAT1NPSR1 | |
| SCHEMBL463631 | 0.86 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL440581 | 0.85 | DGAT1 (0.60) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885NPSR1 2899/4885KMT2A 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.